Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223307 · ClinicalTrials.gov registry record · Phase 2
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
A Phase 2 study of Liver Cancer and Liver Metastases, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT07223307 is a Phase 2 study of Liver Cancer and Liver Metastases that is actively recruiting participants, run by Stanford University. The registered enrollment target is 62 participants, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07223307, a Phase 2 study of Liver Cancer and Liver Metastases, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Conditions Studied
Interventions
- RADIATION MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223307
The ClinicalTrials.gov registry entry for NCT07223307 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) is the first listed.
NCT07223307 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07223307 about?
NCT07223307 is a clinical study titled "REGULUS: MRI-guided Adaptive SABR for Liver Cancers". Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
What is the current status of trial NCT07223307?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2026-01-23. Estimated completion is 2030-01.
What conditions does trial NCT07223307 study?
This clinical trial studies the following conditions: Liver Cancer, Liver Metastases, Intrahepatic Cholangiocarcinoma, HCC.
What interventions are being tested in trial NCT07223307?
The interventions under investigation include: MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT07223307?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223307 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.